HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Requiring Infant Formula, Medical Food Shortage Updates Included In US FDA Budget Request

Executive Summary

FDA’s justification report published with Biden administration’s FY2022 federal budget request includes $1.194bn for agency’s food programs, which include its oversight of supplement industry, up from $1.11bn in FY2021 appropriation.

You may also be interested in...



US FDA ‘Closer To Zero’ Meeting On Infant Nutrition Safety And Benefits Set For November

CFSAN launched “C2Z” initiative in April following widespread reports of contamination of baby food products. Agency officials will outline C2Z plan including a four-stage approach for continual improvement and additional work related to levels of toxic elements in food.

US House Appropriators Have Little Left To Say About Allowing Cannabinoids In Supplements

Appropriation Committee’s report with FDA’s FY2022 funding bill appears to signal that other than getting something done, members have little to say about establishing lawful use of hemp-derived cannabinoids in non-drug products.

House Appropriators Go Low On FDA's Budget

Appropriation set for CFSAN and ORA’s related field activities is $1.16bn, up slightly from the FY2021 level of $1.1bn, and for CDER and ORA’s related activities is $2.1bn, up $100m from current funding.

Related Content

Topics

UsernamePublicRestriction

Register

RS151381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel